NONOF NOVO NORDISK A/S
- 132.200
- +1.500+1.15%
NOVO NORDISK A/S News
Novo Nordisk to Test Obesity Drugs Including Wegovy in Alcohol Use
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
Patients using Novo Nordisk's (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over a four-year period, as per data revealed by the company on
Novo Nordisk A/S: Once-weekly and Once-monthly Mim8 Demonstrate Superior Reduction of Treated Bleeding Episodes Compared to On-demand and Prior Prophylaxis Treatment in People With Haemophilia A in the Frontier 2 Trial
One in Eight U.S. Adults Admits to GLP-1 Usage as Public Awareness Surges
Novo Nordisk A/S Purchases B Shares Worth DKK 5,428 Million From Novo Holdings A/S Under the 2024 Share Repurchase Programme
Weight-loss Drug Competition Heats Up. Is Wegovy in Trouble?
Novo Nordisk Slides While Moderna Pops: Tale of Two Pharma Stocks
Novo Nordisk Sales up 26% Driven by GLP-1s, Misses 11% on Wegovy
Novo Nordisk CEO on Weight Loss Drugs' 'Exciting Growth Story'
Trending Tickers: Shell, Apple, Novo Nordisk and Standard Chartered
Novo Nordisk GAAP EPADR of DKK 5.68, Revenue of DKK 65.35B; Updates FY24 Outlook
Novo Nordisk's Sales Increased by 22% in Danish Kroner and by 24% at Constant Exchange Rates to DKK 65.3 Billion in the First Three Months of 2024
Apple, Novo Nordisk Earnings, Jobless Claims: What to Watch
Eli Lilly Reports $2 Billion From Mounjaro, Zepbound in Q1 2024
Why These Analysts Are Bullish on Healthcare Stocks
Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024
Novo Nordisk A/S – Reduction of the Share Capital
Weight Loss Drugs and the Many Use Cases in Medical Treatments
Eli Lilly Obesity Therapy Succeeds in Late-stage Trials for Sleep Disorder
GLP-1s Benefit Parkinson's: Barclays Sees Implications Across Biopharma
Analysis
Price Target
No Data
